Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001299632 | SCV001488734 | uncertain significance | Lymphoproliferative syndrome 2 | 2022-11-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 1003118). This variant has not been reported in the literature in individuals affected with CD27-related conditions. This variant is present in population databases (rs766655010, gnomAD 0.1%). This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 255 of the CD27 protein (p.Glu255Gln). |
Ambry Genetics | RCV003365308 | SCV004064783 | uncertain significance | Inborn genetic diseases | 2023-06-29 | criteria provided, single submitter | clinical testing | The c.763G>C (p.E255Q) alteration is located in exon 6 (coding exon 6) of the CD27 gene. This alteration results from a G to C substitution at nucleotide position 763, causing the glutamic acid (E) at amino acid position 255 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |